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Abstract
Background. Alpha 2 (a2)-adrenoceptor agonists may be useful for their potential to increase or prolong opioid analgesia while
attenuating the development of opioid tolerance. The purpose of this study was to investigate the effects of dexmedetomidine
and guanfacine (a2-adrenoceptor agonists) on morphine analgesia and tolerance in rats.
Methods. Adult male Wistar albino rats weighing 195–205 g were used. To constitute morphine tolerance, animals received
morphine (50 mg/kg) once daily for 3 days. After the last dose of morphine had been injected on day 4, morphine tolerance
was evaluated by analgesia tests. The analgesic effects of dexmedetomidine (20 mg/kg), guanfacine (0.5 mg/kg), MK-467
(0.25 mg/kg), and morphine were estimated at 30-min intervals (0, 30, 60, 90, and 120 min) by tail-ﬂick and hot-plate
analgesia tests.
Results. Our ﬁndings indicate that dexmedetomidine and guanfacine attenuated the expression of morphine tolerance.
In addition, administration of dexmedetomidine with morphine increased morphine analgesia. On the contrary, data
suggested that MK-467 (an a2-adrenoceptor antagonist) decreased morphine analgesia and increased morphine tolerance
in analgesia tests.
Conclusion. In conclusion, we observed that co-injection of dexmedetomidine or guanfacine with morphine attenuated the
expression of tolerance to the analgesic effect of morphine and that dexmedetomidine enhanced the morphine analgesia.
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Introduction
Morphine and related opioid drugs produce potent
analgesia by activating speciﬁco p i o i dr e c e p t o r s
expressed in brain, spinal cord, and peripheral tissues.
Chronic administration of these drugs, however, leads
to the development of both tolerance and dependence,
limiting the utility of opioids in the management of
severe pain syndromes. The mechanisms underlying
the development of tolerance are complex and not
completely understood. There are several possible
explanations for the development of opioid tolerance,
including opioid peptide receptor desensitization,
up-regulation of the cAMP pathway (supersensi-
tization of adenylyl cyclases, receptor coupling with
stimulatory G-proteins), induction of nitric oxide
(NO)-cGMP systems, and protein kinase-dependent
neuroadaptativechangesinsignaltransductioncascades
(second-messenger-dependent protein kinases and
G-protein-coupled receptor kinases) (1–3). We also
recently demonstrated that the nitric oxide–cGMP
signal pathway plays a pivotal role in developing
tolerance to the analgesic effect of morphine (4).
The noradrenergic system plays an important role
in opioid actions. Alpha 2 (a2)-adrenoceptor agonists
potentiate morphine analgesia, and there is analgesic
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DOI: 10.3109/03009734.2011.597889synergism between endogenous a2-noradrenergic
and opioidergic mechanisms in the spinal cord of
mice and rats (5,6). Substance P-induced behavioral
nociceptive responses are inhibited by intrathecally
administered opioid agonists and a2-adrenoceptor
agonists in mice (7). In addition, the a2-adrenoceptor
antagonist, yohimbine, attenuates the analgesic
effects of opioid agonists in the rat (8). Three a2-
adrenoceptor subtypes have been identiﬁed in
humans and in mice, i.e. a2A-, a2B-, and a2C-
adrenoceptors. All three are coupled to Gi/o-type
G-proteins, and their activation induces similar
second-messenger responses as those mediated by
opioid peptide receptor activation, i.e. inhibition of
adenylyl cyclases, activation of hyperpolarizing K
+
channels, and inhibition of Ca
2+ channels. In the
central nervous system (CNS), presynaptically local-
ized a2-adrenoceptors inhibit the release of norad-
renaline and several other neurotransmitters. The
a2A-adrenoceptor is the principal a2-adrenoceptor
subtype found in the CNS. The analgesic and sed-
ative properties of a2-adrenoceptor agonists are
mainly attributed to a2A-adrenoceptor activation, as
evidenced by recent studies on mice lacking func-
tional a2A-adrenoceptors (9,10).
Dexmedetomidine is a subtype-non-selective
a2-adrenoceptor agonist. It has potent sympatholytic,
analgesic, sedative, and anesthetic effects in animals
(11–13) and in humans (14), and it is in clinical use as
a sedative agent in the intensive care setting (15).
Dexmedetomidine decreases the turn-over of the
monoamine neurotransmitters noradrenaline, dopa-
mine, and serotonin (5-HT) in brains of rats (16), but
this effect was absent in mice lacking a2A-adrenocep-
tors. Also, other typical a2-adrenoceptor-mediated
effects of dexmedetomidine, such as inhibition of
locomotor activity and hypothermia, were very
markedly attenuated, but not totally abolished, in
a2A-adrenoceptor-deﬁcient mice (11). The alpha-2
agonist guanfacine does not discriminate between the
three subtypes of alpha-2 receptors, although guanfa-
cine has somewhat higher afﬁnity for the 2A versus 2B
and 2C subtypes (17).
Rapiddevelopment of tolerance limitsthe usefulness
of morphine and other potent opioids in long-term
treatment. Morphine tolerance is a complex pheno-
menon, involving also the brain noradrenergic system
(18). There is much evidence that the brain nora-
drenergic system is involved in many of the actions of
morphine (19,20), but the role of a2-adrenoceptors
on the mechanisms of development of tolerance to
morphine are still unclear. Thus, the aim of the present
study was to determine the effects of dexmedeto-
midine and guanfacine, as a2-adrenoceptor agonists,
on morphine analgesia and tolerance in rats.
Materials and methods
Animals
The experiments were performed on adult male
Wistar albino rats weighing 195–205 g. Animals
were housed four per cage in a room maintained at
22C ± 1C with an alternating 12 h dark/12 h light
cycle and free access to water and food. Animals were
acclimatized to laboratory conditions before the test.
All experiments were carried out blindly between
09.00 and 17.00 h. The experimental protocols
were approved by the Cumhuriyet University Animal
Ethics Committee (license number: 87/Ethic).
Drugs
Dexmedetomidine, guanfacine, MK-467 (Sigma-
Aldrich, USA), and morphine sulphate (Cumhuriyet
University Hospital, Turkey) were dissolved in phys-
iological saline. Solutions were freshly prepared on
the days of experimentation. Subcutaneous (s.c.)
morphine (5 mg/kg), intraperitoneal (i.p.) dexmede-
tomidine (20 mg/kg), guanfacine (0.5 mg/kg), and
MK-467 (0.25 mg/kg) were administered before the
analgesia tests.
Induction of morphine tolerance
To constitute morphine tolerance, a 3-day cumulative
dosing regimen was used. The treatment schedule
consisted of twice daily s.c. doses of morphine given at
30 mg/kg (a.m.) and 45 mg/kg (p.m.) on day 1; 60 and
90 mg/kg on day 2; and 120 mg/kg twice on day 3.
Animals were assessed for tolerance on the 4th day, as
described by Way et al. (21). Tolerance was assessed
based on loss of the antinociceptive effects of a test
dose (5 mg/kg; s.c.) of morphine. On day 4, tail-ﬂick
and hot-plate tests were done for each rat to average
them as a base-line latency; then a challenge dose of
morphine (5 mg/kg; s.c.) was injected; 30 min after
the morphine injection further tail-ﬂick and hot-
plate tests were performed for evaluations of the
development of tolerance to morphine.
In saline-treated rats, saline was administered twice
daily for 3 days according to the same injection
schedule.
Antinociceptive tests
To evaluate thermal nociception, we used a standard-
ized tail-ﬂick apparatus (May TF 0703 Tail-ﬂick Unit;
Commat, Turkey). The radiant heat source was
focused on the distal portion of the tail at 3 cm after
administration of the vehicle and study drugs.
Following vehicle or compound administration,
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intensity was adjusted so that basal TFL occurred at
2.9 ± 0.5 s. Animals with a base-line TFL below 2.4 or
above 3.4 s were excluded from further testing. The
cut-off latency was set at 15 s to avoid tissue damage.
Any animal not responding after 15 s was excluded
from the study. The hyperalgesic response in the tail-
withdrawal test is generally attributed to central
mechanisms (22,23).
A second analgesia test was that of hot-plate testing.
In this test, animals were individually placed on
a hot-plate (May AHP 0603 Analgesic Hot-plate;
Commat, Turkey) with the temperature adjusted to
55C ± 0.5C. The latency to the ﬁrst sign of paw
lickingor jump response to avoid the heat was taken as
an index of the pain threshold; the cut-off time was
30 s in order to avoid damage to the paws. The
antinociceptive response on the hot-plate is consid-
ered to result from a combination of central and
peripheral mechanisms (22).
Experimental protocols
Antinociceptive effects of dexmedetomidine, guanfa-
cine, MK-467, and morphine were estimated at
30-min intervals (0, 30, 60, 90, and 120 min) by tail-
ﬂickandhot-platetestsinrats(n=7–8).Afterinduction
of morphine tolerance, the analgesic response to the
challenge dose was determined again on day 4 at
30-min intervals after the same morphine (5 mg/
kg challenge dose; s.c.) injection as on the ﬁrst day.
Toevaluatetheeffectsofdexmedetomidine,guanfacine,
and MK-467 on expression of morphine tolerance,
morphine-tolerant animals received dexmedetomidine
(20 mg/kg; i.p.), guanfacine (0.5 mg/kg; i.p.), or
MK-467(0.25mg/kg;i.p.).Inthesaline-treatedgroup,
animalsreceivedsaline(10mL/kg)insteadofmorphine.
Data analysis
In order to calculate percent maximal antinociceptive
effects (% MPE), tail-withdrawal latencies (tail-ﬂick)
and lick/escape latencies (hot-plate) were converted to
percent antinociceptive effect using the following
equation (equation 1):
%[ ( ) /
() ] . (
MPE test latency
Eq
=−
×
base-line
cut-off base-line − 100 . .) 1
Statistical analysis
Antinociceptive effects of the drugs were measured as
tail-ﬂick and hot-plate latencies in all groups for each
rat and converted to % MPE. The data were analyzed
by analysis of variance (ANOVA) followed by Tukey
test. All data are presented as means ± SEM. The level
of signiﬁcance was set at p < 0.05.
Results
Effects of dexmedetomidine on morphine analgesia and
tolerance
Tukey’s test indicated that pretreatment of animals
with dexmedetomidine reduced (increased mean of %
MPE value) the expression of tolerance to the mor-
phine antinociceptive effect in both tail-ﬂick (p < 0.01;
Figure1A)andhot-platetests(p<0.01;Figure1B).In
addition to this, administration of dexmedetomidine
with morphine increased the antinociceptive effect of
morphine in tail-ﬂick (p < 0.05; Figure 1A) and hot-
plate tests (p < 0.05; Figure 1B). The peak value was
observed at 30 min after administration of morphine
and dexmedetomidine in analgesia tests (tail-ﬂick:
62.70 ± 5.6 and hot-plate: 75.40 ± 5.9). Furthermore,
these data suggested that dexmedetomidine alone has
got an analgesic effect (p < 0.05).
Effects of guanfacine on morphine analgesia and
tolerance
It was found that guanfacine reduced the expression
of tolerance to the morphine analgesic effect in tail-
ﬂick (p < 0.01; Figure 2A) and hot-plate tests
(p < 0.01; Figure 2B). However, administration of
guanfacine did not increase the antinociceptive effect
of morphine in tail-ﬂick (Figure 2A) and hot-
plate (Figure 2B) tests. In their analgesia tests the
peak value of the morphine group was observed after
60 min. Furthermore, there was no evidence to sug-
gest that guanfacine alone had an analgesic effect.
Effects of MK-467 on morphine analgesia and tolerance
Systemic administration of MK-467 (a2-adrenocep-
tor antagonist) together with morphine produced a
decrease in % MPE in both the tail-ﬂick (p < 0.01;
Figure 3A) and hot-plate (p < 0.01; Figure 3B) assays
when compared to rats given morphine only. Pre-
treatment of animals with MK-467 increased the
expression of tolerance to the morphine antinocicep-
tive effect in tail-ﬂick and hot-plate tests (Tukey;
p < 0.05 and p > 0.05, respectively). Also,
MK-467 alone had no analgesic effect.
Analgesic effects of different doses of dexmedetomidine
In dose–response studies of the dexmedetomidine
effect, the analgesic response was measured for
three different doses of dexmedetomidine (5, 10, and
240 S. Gursoy et al.20mg/kg;i.p.)at30-minintervals(0minand30min)by
tail-ﬂick and hot-plate tests. The maximum analgesic
effect was observed after administration of 20 mg/
kg dexmedetomidine (45.50 ± 6.90 for tail-ﬂick test
and 41.30 ± 7.13 for hot-plate test). The % MPE
produced by dexmedetomidine (20 mg/kg) was higher
than in the other groups (p < 0.01; Figure 4A) and hot-
plate test (p < 0.01; Figure 4B).
Discussion
In this study, we demonstrated that the a2-adreno-
ceptor agonists dexmedetomidine and guanfacine
play a signiﬁcant role in morphine analgesia and
tolerance. Obtained data suggested that co-injection
of morphine with dexmedetomidine increased the
analgesic effects of morphine and attenuated the
development of tolerance to morphine analgesia.
Similarly, the data showed that guanfacine reduced
the expression of tolerance to the analgesic effect of
morphine. On the other hand, the a2-adrenoceptor
antagonist MK-467 decreased the analgesic effects of
morphine and increased the expression of tolerance to
morphine. All these results supported the idea that the
a2-adrenoceptor agonists attenuate development of
tolerance to morphine analgesia.
Pain modulation is a dynamic process, which
includes many interactions among complex ascen-
ding and descending neuronal systems (24,25).
Opioidergic and noradrenergic pathways have very
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Figure 1. Effects of dexmedetomidine (DEX; 20 mg/kg; i.p.) on morphine analgesia and tolerance in tail-ﬂick (A) and hot-plate (B) tests. Each
point represents the mean ± SEM of percent of maximal possible effect (% MPE) for 8 rats. *p < 0.05 compared to morphine group,
**p < 0.01 compared to morphine-tolerant group.
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Activation of opioid and a2-adrenergic receptors inhi-
bits the transmission of pain sensation at spinal and
supraspinal levels. While a2-adrenoceptors inhibit
nociception and have analgesic synergy with opioids,
there is evidence that a1-adrenoceptors may facilitate
nociception and oppose opioid analgesia. Microinjec-
tion of the a1-adrenoceptor antagonist, prazosin, into
the nucleus raphe magnus, a brain nucleus involved in
nociceptive processing, produces antinociception
similarly to the a2-adrenoceptor agonist clonidine
(28). It has also been reported that prazosin augments
clonidine analgesia in amphibians (29). Morphine
microinjection into the ventrolateral periaqueductal
gray inhibits nociceptive tail responses, an effect
mediated by acetylcholine, 5-HT, and a2-adrenergic
receptors in the spinal cord. In some experiments,
however, microinjection of morphine into the peria-
queductal gray has also facilitated nociceptive
responses; this facilitation of hot-plate responses
was mediated by a1-adrenoceptors in the spinal
cord (30). Noradrenaline has an important role in
the modulation of pain transmission especially at the
level of the spinal cord (31). In accordance with our
ﬁndings, Belgrade et al. (32) informed that the admin-
istration of a2-adrenoceptor agonists increased the
morphine antinociceptive effect in patients. Intrathe-
cal or direct spinal injection of noradrenaline pro-
duces antinociception and decreased dorsal horn
neuronal activity. However, noradrenaline has two
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Figure 2. Effects of guanfacine (0.5 mg/kg; i.p.) on morphine analgesia and tolerance in tail-ﬂick (A) and hot-plate (B) tests. Each point
represents the mean ± SEM of percent of maximal possible effect (% MPE) for 7 rats. *p < 0.01 compared to saline group, **p < 0.05 compared
to morphine-tolerant group.
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vation of a1A- but not a1B/D-adrenoceptors medi-
ates potentiation of spinal nociceptive reﬂexes (33).
Noradrenaline enhances motoneuronal responses
to stimulation of nearby ventral interneurons via
activation of a1A-adrenoceptors (34). The principal
adrenoceptor subtype mediating noradrenaline anti-
nociception has recently been identiﬁed as the a2A-
adrenoceptor based on studies in gene-targeted mice
(11). In addition to this, a2C-adrenoceptors may also
contribute to spinal analgesia (35). Increased central
noradrenergic activity potentiates morphine analgesia
(36), but acute morphine administration inhibits nor-
adrenergic neurons in the locus coeruleus and
reduces noradrenaline release in its projection areas
(37). Some centrally acting sympathomimetic agents,
such as ephedrine, which act primarily through
enhancing the release of stored catecholamines,
potentiate morphine analgesia, although they do not
have analgesic effects when given alone (19,38).
The mechanisms of opioid tolerance comprise
changes at the receptor level as well as at downstream
sites (39). Adaptational changes directly affecting the
receptors involve their phosphorylation by G-protein-
coupled receptor kinases (GRK) and subsequent
binding of b-arrestin, resulting in uncoupling of
the receptor from its associated G-proteins (receptor
desensitization). Subsequent to receptor uncoup-
ling, cell surface-located receptors may become inter-
nalized and either dephosphorylated and recycled
Tail-flick
Saline
Morphine
MK-467
MK-467+Morphine
MK-467+Morphine tolerant
Morphine tolerant
*
**
*
**
60
50
40
%
 
M
P
E
30
20
10
0
Hot-plate
70
60
50
40
%
 
M
P
E
30
20
10
0
03 0 6 0
Time (min)
90 120
0
30 60
Time (min)
90 120
Saline
Morphine
MK-467
MK-467+Morphine
MK-467+Morphine tolerant
Morphine tolerant
A
B
Figure 3. Effects of MK-467 (0.25 mg/kg; i.p.) on morphine analgesia and tolerance in tail-ﬂick (A) and hot-plate (B) tests. Each point
represents the mean ± SEM of percent of maximal possible effect (% MPE) for 7 rats. *p < 0.05 compared to MK-467 + morphine group,
**p < 0.01 compared to MK-467 + morphine-tolerant group.
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lysosomes for degradation (40). Accordingly, uncou-
pling and internalization effectively contribute to
desensitization of opioid peptide receptor signaling
and, thus, to the phenomenon of opioid tolerance. In
addition, there are also other alterations of opioid
peptide receptor signaling. Acute administration of
opioid agonists decreases cellular cAMP levels, but
prolonged treatment triggers up-regulation of adeny-
lyl cyclase activity (41). This may be one of the
cellular adaptations that underlie neuronal hyperac-
tivity during opioid tolerance and withdrawal (42).
The m-opioid peptide receptor response to the anti-
nociceptive drug morphine can be differently regu-
lated at different levels of the pain perception system.
It appears that b-arrestin-mediated mechanisms of
desensitization are major contributors to the devel-
opment of tolerance at both supraspinal and spinal
sites. Elimination of b-arrestin-mediated mechanisms
by gene targeting has revealed that a protein kinase C
(PKC)-mediated mechanism also contributes to
the development of morphine tolerance at the spinal
level (43).
Theinteractionsbetweencentral noradrenergicand
opioidergicmechanismsarecomplex.Thelocalization
of and the receptor subtypes involved in the interac-
tions of these systems with regard to antinociception
and analgesic tolerance are still unclear. However,
the obtained data suggested that dexmedetomidine
increased the antinociceptive effect of morphine. In
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244 S. Gursoy et al.addition,wealsodeterminedthatthea2-adrenoceptor
agonists dexmedetomidine and guanfacine attenuated
the expression of tolerance to the analgesic effect of
morphine.
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